Literature DB >> 6212200

Exfoliative dermatitis from captopril.

A M Solinger.   

Abstract

Captopril, an angiotensin converting enzyme blocker, has recently been released for limited clinical use in the treatment of refractory congestive heart failure and severe hypertension. The only major dermatologic side effects from this medication have been either an urticarial or an erythematous, maculopapular eruption. This paper presents what I believe to be the first reported case of exfoliative erythroderma associated with the use of captopril. Although this medication may be lifesaving with its minimal side effects, close attention should be paid to the dermatologic side effects of this drug.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6212200

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  4 in total

Review 1.  Renal failure and ACE inhibition: how much is too much?

Authors:  M-L Gross; M Adamczak; E Ritz
Journal:  Z Kardiol       Date:  2005-02

Review 2.  Selecting appropriate antihypertensive drug dosages.

Authors:  G D Johnston
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

3.  Severe cutaneous reactions to captopril.

Authors:  M J Goodfield; L G Millard
Journal:  Br Med J (Clin Res Ed)       Date:  1985-04-13

Review 4.  Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure.

Authors:  J A Romankiewicz; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-01       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.